Gilead’s Letairis Label Updated For Fluid Retention
This article was originally published in The Pink Sheet Daily
Executive Summary
Language similar to wording on competitor Tracleer.
You may also be interested in...
Actelion’s Tracleer Hangs On Against Label-Dampened Letairis
Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.
Actelion’s Tracleer Hangs On Against Label-Dampened Letairis
Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.
Encysive Rules Out FDA Dispute Resolution Path For Thelin NDA
Firm expects to have 35 sales reps for European, Canadian launch of Thelin by early next year, CEO says.